Stay updated with breaking news from Long Term Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over...
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis - read this article along with other careers information, tips and advice on BioSpace
Press release content from Business Wire. The AP news staff was not involved in its creation. Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society May 11, 2021 GMT LYON, France--(BUSINESS WIRE)--May 11, 2021-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced its participation at the 64 th Annual Meeting of the Japan Diabetes Society (May 20-22, 2021). Three presentations on...
Poxel SA: Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society th Annual Meeting of the Japan Diabetes Society (May 20-22, 2021). Three presentations on Imeglimin will be included in an oral session for large clinical studies in the afternoon (2:30 pm to 3:40 pm JST) of May 20. These presentations will be focused on the analysis and interpretation of clinical data derived from Phase 2 and Phase 3 (TIMES program) trials with Imeglimin, Poxel's novel antidiabetic investigational drug, where Japanese patients with type 2 diabetes (T2DM) were enrolled and stu...